Literature DB >> 22072755

Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease.

Christopher P Desmond1, Silvana Gaudieri, Ian R James, Katja Pfafferott, Abha Chopra, George K Lau, Jennifer Audsley, Caroline Day, Sarah Chivers, Adam Gordon, Peter A Revill, Scott Bowden, Anna Ayres, Paul V Desmond, Alexander J Thompson, Stuart K Roberts, Stephen A Locarnini, Simon A Mallal, Sharon R Lewin.   

Abstract

Hepatitis B virus (HBV)-specific T-cell responses are important in the natural history of HBV infection. The number of known HBV-specific T-cell epitopes is limited, and it is not clear whether viral evolution occurs in chronic HBV infection. We aimed to identify novel HBV T-cell epitopes by examining the relationship between HBV sequence variation and the human leukocyte antigen (HLA) type in a large prospective clinic-based cohort of Asian patients with chronic HBV infection recruited in Australia and China (n = 119). High-resolution 4-digit HLA class I and II typing and full-length HBV sequencing were undertaken for treatment-naïve individuals (52% with genotype B, 48% with genotype C, 63% HBV e antigen [HBeAg] positive). Statistically significant associations between HLA types and HBV sequence variation were identified (n = 49) at 41 sites in the HBV genome. Using prediction programs, we determined scores for binding between peptides containing these polymorphisms and associated HLA types. Among the regions that could be tested, HLA binding was predicted for 14/18 (78%). We identified several HLA-associated polymorphisms involving likely known anchor residues that resulted in altered predicted binding scores. Some HLA-associated polymorphisms fell within known T-cell epitopes with matching HLA restriction. Enhanced viral adaptation (defined as the presence of the relevant HLA and the escaped amino acid) was independently associated with HBeAg-negative disease (P = 0.003). Thus, HBV appears to be under immune pressure in chronic HBV infection, particularly in HBeAg-negative disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072755      PMCID: PMC3255822          DOI: 10.1128/JVI.05308-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

Review 1.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

2.  T cell receptor usage of virus-specific CD8 cells and recognition of viral mutations during acute and persistent hepatitis B virus infection.

Authors:  M K Maini; S Reignat; C Boni; G S Ogg; A S King; F Malacarne; G J Webster; A Bertoletti
Journal:  Eur J Immunol       Date:  2000-11       Impact factor: 5.532

3.  New allele frequency database: http://www.allelefrequencies.net.

Authors:  D Middleton; L Menchaca; H Rood; R Komerofsky
Journal:  Tissue Antigens       Date:  2003-05

Review 4.  Chronic hepatitis B virus infection in Asian countries.

Authors:  I Merican; R Guan; D Amarapuka; M J Alexander; A Chutaputti; R N Chien; S S Hasnian; N Leung; L Lesmana; P H Phiet; H M Sjalfoellah Noer; J Sollano; H S Sun; D Z Xu
Journal:  J Gastroenterol Hepatol       Date:  2000-12       Impact factor: 4.029

5.  Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402, the most common HLA class I allele in East Asia.

Authors:  Y Sobao; K Sugi; H Tomiyama; S Saito; S Fujiyama; M Morimoto; S Hasuike; H Tsubouchi; K Tanaka; M Takiguch
Journal:  J Hepatol       Date:  2001-06       Impact factor: 25.083

6.  Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice.

Authors:  Takahiro Okazaki; Masaki Terabe; Andrew T Catanzaro; C David Pendleton; Robert Yarchoan; Jay A Berzofsky
Journal:  J Virol       Date:  2006-08-18       Impact factor: 5.103

7.  Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.

Authors:  S R Lewin; R M Ribeiro; T Walters; G K Lau; S Bowden; S Locarnini; A S Perelson
Journal:  Hepatology       Date:  2001-11       Impact factor: 17.425

8.  Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level.

Authors:  Corey B Moore; Mina John; Ian R James; Frank T Christiansen; Campbell S Witt; Simon A Mallal
Journal:  Science       Date:  2002-05-24       Impact factor: 47.728

9.  A revised evolutionary history of hepatitis B virus (HBV).

Authors:  Mario Ali Fares; Edward C Holmes
Journal:  J Mol Evol       Date:  2002-06       Impact factor: 2.395

10.  Common HLA-B8-DR3 haplotype in Northern India is different from that found in Europe.

Authors:  C S Witt; P Price; G Kaur; K Cheong; U Kanga; D Sayer; F Christiansen; N K Mehra
Journal:  Tissue Antigens       Date:  2002-12
View more
  16 in total

1.  CD8+ T-Cell Response-Associated Evolution of Hepatitis B Virus Core Protein and Disease Progress.

Authors:  George F Gao; Jingmin Zhao; Yu Zhang; Yan Wu; Mengmeng Deng; Dongping Xu; Xiaodong Li; Zhihui Xu; Jun Hu; Han Zhang; Kefang Liu; Yingze Zhao; Feng Gao; Shengli Bi; William J Liu; Songdong Meng
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

Review 2.  Induced immunity against hepatitis B virus.

Authors:  Zeinab Nabil Ahmed Said; Kouka Saadeldin Abdelwahab
Journal:  World J Hepatol       Date:  2015-06-28

3.  HLA-DP polymorphisms affect the outcomes of chronic hepatitis B virus infections, possibly through interacting with viral mutations.

Authors:  Qi Zhang; Jianhua Yin; Yuwei Zhang; Yang Deng; Xiaowei Ji; Yan Du; Rui Pu; Yifang Han; Jun Zhao; Xue Han; Hongwei Zhang; Guangwen Cao
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

4.  Immunoprevalence and immunodominance of HLA-Cw*0801-restricted T cell response targeting the hepatitis B virus envelope transmembrane region.

Authors:  Anthony T Tan; Pimpayao Sodsai; Adeline Chia; Eglantine Moreau; Melissa H Y Chng; Christine Y L Tham; Zi Zong Ho; Nasirah Banu; Nattiya Hirankarn; Antonio Bertoletti
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

Review 5.  T-cell responses in hepatitis B and C virus infection: similarities and differences.

Authors:  Julia Schmidt; Hubert E Blum; Robert Thimme
Journal:  Emerg Microbes Infect       Date:  2013-03-27       Impact factor: 7.163

6.  The Functional Difference of Dendritic Cells in HBeAg Negative Chronic Hepatitis B Patients with Three Different Spleen Deficiency Syndromes and the Therapeutic Evaluation of Chinese Medicine Intervention Based on Syndrome Differentiation.

Authors:  Lei Wang; Li Zhang; Xiaoxia Feng; Lianjun Xing; Wei Zhang; Kaiping Jiang; Haiyan Song; Guang Ji
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-29       Impact factor: 2.629

7.  Hepitopes: A live interactive database of HLA class I epitopes in hepatitis B virus.

Authors:  Sheila Lumley; Howard Noble; Martin J Hadley; Liz Callow; Amna Malik; Yi Yi Chua; Owen J Duffey; Natalia Grolmusova; Arvind Kumar; Samuel Ravenscroft; Jonathan I Spencer; Christoph Neumann-Haefelin; Robert Thimme; Monique Andersson; Paul Klenerman; Eleanor Barnes; Philippa C Matthews
Journal:  Wellcome Open Res       Date:  2016-11-15

Review 8.  Hepatitis B Virus Adaptation to the CD8+ T Cell Response: Consequences for Host and Pathogen.

Authors:  Sheila F Lumley; Anna L McNaughton; Paul Klenerman; Katrina A Lythgoe; Philippa C Matthews
Journal:  Front Immunol       Date:  2018-07-16       Impact factor: 7.561

9.  Analysis of ultra-deep pyrosequencing and cloning based sequencing of the basic core promoter/precore/core region of hepatitis B virus using newly developed bioinformatics tools.

Authors:  Mukhlid Yousif; Trevor G Bell; Hatim Mudawi; Dieter Glebe; Anna Kramvis
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

10.  The Possible Role of TLR2 in Chronic Hepatitis B Patients with Precore Mutation.

Authors:  Malihe Moradzadeh; Sirous Tayebi; Hossein Poustchi; Kourosh Sayehmiri; Parisa Shahnazari; Elnaz Naderi; Ghodratollah Montazeri; Ashraf Mohamadkhani
Journal:  Adv Virol       Date:  2013-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.